Details of the Drug

General Information of Drug (ID: DM0K2T1)

Drug Name

1-(2-Furan-2-yl-ethyl)-3-thiazol-2-yl-thiourea

Synonyms

172505-85-0; Thiourea, N-(2-(2-furanyl)ethyl)-N'-2-thiazolyl-; Thiourea, N-[2-(2-furanyl)ethyl]-N'-2-thiazolyl-; PETT Analog 29; PETT Furyl deriv.; AC1MHDKI; CHEMBL359410; BDBM1922; 1-[2-(furan-2-yl)ethyl]-3-(1,3-thiazol-2-yl)thiourea; DTXSID70169335; N-(2-(2-furyl)ethyl)-N-(2-thiazolyl)thiou; 1-[2-(2-furyl)ethyl]-3-thiazol-2-yl-thiourea; 1-(2-Thiazolyl)-3-[2-(furan-2-yl)ethyl]thiourea

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

253.3

Topological Polar Surface Area (xlogp)

1.9

Rotatable Bond Count (rotbonds)

4

Hydrogen Bond Donor Count (hbonddonor)

2

Hydrogen Bond Acceptor Count (hbondacc)

4

Chemical Identifiers

Formula: C10H11N3OS2
IUPAC Name: 1-[2-(furan-2-yl)ethyl]-3-(1,3-thiazol-2-yl)thiourea
Canonical SMILES: C1=COC(=C1)CCNC(=S)NC2=NC=CS2
InChI: InChI=1S/C10H11N3OS2/c15-9(13-10-12-5-7-16-10)11-4-3-8-2-1-6-14-8/h1-2,5-7H,3-4H2,(H2,11,12,13,15)
InChIKey: HSLMRTQANDUJDA-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3001099
CAS Number: 172505-85-0
TTD ID: D09CNT

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus Reverse transcriptase (HIV RT)	TT84ETX	POL_HV1B1	Inhibitor	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36.
2	Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
3	HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
4	A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6	Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
7	Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
8	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.